New JNE Special Issue: Current status and cutting-edge insights in Peptide Receptor Radionuclide Therapy
NEW! Journal of Neuroendocrinology is pleased to announce the publication of a Special Issue on the current status and cutting-edge insights in Peptide Receptor Radionuclide Therapy.
Peptide Receptor Radionuclide Therapy (PRRT) is a highly targeted and effective form of radiopharmaceutical therapy (RPT) with minimal side effects for treating neuroendocrine tumours with an abundance or overexpression of somatostatin receptors. PRRT is a well-established as a diagnostic and treatment for well-differentiated neuroendocrine tumours (NETs) as well as other cancers, e.g. when using prostate-specific membrane antigen (PSMA) for prostate cancer.
This special issue reviews current evidence on the efficacy and toxicity of PRRT in its approved indications, explores methods for evaluating treatment response, and discusses emerging evidence for its use in unlicensed indications. Additionally, it examines strategies to enhance the therapeutic effects of PRRT. As peptide ligands are the major physiological and pathophysiological regulators in humans there is vast potential for the development of novel PRRTs.
The Special Issue is edited by Dr Shaunak Navalkissoor and Professor Robert Millar. On the issue’s publication, Professor Millar said:
"This is a groundbreaking new arena for the Translational and Clinical Strand of JNE. I am delighted this special issue will move JNE towards becoming the ‘go to’ repository for PRRT research."
The special issue comprises:
- An editorial
- 10 reviews
- 6 original research articles
Papers include topics such as:
- Current status of peptide receptor radionuclide therapy in grade 1 and 2 gastroenteropancreatic neuroendocrine tumours
- Toxicity Manifestations encountered in PRRT setting
- Somatostatin Receptor-linked α-Particle Therapy in Neuroendocrine Tumours
- Assessment of response to PRRT including anatomical and molecular imaging as well as novel biomarkers
- Frontiers in Radiopharmaceuticals for Neuroendocrine Tumors
- Developing a peripheral blood RNA-Seq based NETseq Ensemble Classifier: A potential novel tool for non-invasive detection and treatment response assessment in Neuroendocrine Tumors patients receiving 177Lu-DOTATATE PRRT
Read the Special Issue: onlinelibrary.wiley.com/doi/abs/10.1111/jne.70014
